Table 1a.
Baseline characteristics of German patients with IBD, stratified by prior exposure to an ADA RP or a biosimilar.
| Characteristic | All patients, N = 3362 | ADA-naïve patients, n = 1828 | ADA-experienced patients, n = 1534 a |
|---|---|---|---|
| Age, years, mean (SD) | 40.9 (14.4) | 40.1 (14.2) | 41.9 (14.7) |
| Sex b , n (%) | |||
| Female | 1637 (56.1) | 887 (55.3) | 750 (57.1) |
| Male | 1280 (43.9) | 716 (44.7) | 564 (42.9) |
| Region, n (%) | |||
| North | 311 (9.3) | 144 (7.9) | 167 (10.9) |
| West | 1499 (44.6) | 804 (44.0) | 695 (45.3) |
| South | 1160 (34.5) | 656 (35.9) | 504 (32.9) |
| East | 392 (11.7) | 224 (12.3) | 168 (11.0) |
| Treating specialty, n (%) | |||
| Dermatologist | 2 (0.1) | 1 (0.1) | 1 (0.1) |
| Gastroenterologist | 2468 (73.4) | 1346 (73.6) | 1122 (73.1) |
| Rheumatologist | 98 (2.9) | 46 (2.5) | 52 (3.4) |
| Unknown | 794 (23.6) | 435 (23.8) | 359 (23.4) |
| Treatment setting, n (%) | |||
| Hospital based | 506 (15.1) | 284 (15.5) | 222 (14.5) |
| Office based | 2856 (85.0) | 1544 (84.5) | 1312 (85.5) |
| Prior treatment at baseline c , n (%) | |||
| Glucocorticoid | 1410 (41.9) | 994 (54.4) | 416 (27.1) |
| Immunosuppressive drug | 678 (20.2) | 453 (24.8) | 225 (14.7) |
| Non-ADA TNFi | 225 (6.7) | 184 (10.1) | 41 (2.7) |
| Non-TNFi biologic | 104 (3.1) | 88 (4.8) | 16 (1.0) |
| JAKi | 12 (0.4) | 12 (0.7) | 0 (0.0) |
| Concomitant treatment c , n (%) | |||
| Glucocorticoid | 812 (24.2) | 522 (28.6) | 290 (18.9) |
| Immunosuppressive drug | 327 (9.7) | 187 (10.2) | 140 (9.1) |
| Comorbidities, n (%) | |||
| Hypertension | 410 (12.2) | 196 (10.7) | 214 (14.0) |
| Dyslipidemia | 122 (3.6) | 54 (3.0) | 68 (4.4) |
| Diabetes | 87 (2.6) | 50 (2.7) | 37 (2.4) |
| Endocrinological disease | 244 (7.3) | 109 (6.0) | 135 (8.8) |
| Respiratory disease | 87 (2.6) | 49 (2.7) | 38 (2.5) |
| Peptic ulcer disease | 373 (11.1) | 172 (9.4) | 201 (13.1) |
a
n = 1297 were switched to ABP 501 from ADA RP and n = 237 were switched from other ADA biosimilars.
b
The percentages of females and males are based on 2917 patients with sex data available.
c
Categories are not mutually exclusive. Patients were possibly treated with more than one category of drugs.
ADA, adalimumab; IBD, inflammatory bowel disease; JAKi, Janus Kinase inhibitor; RP, reference product; SD, standard deviation; TNFi, tumor necrosis factor inhibitor.